Antiviral Drug Discovery for SARS-CoV-2
A novel coronavirus (SARS-CoV-2) originally detected in Wuhan, China, has caused an outbreak of viral pneumonia spreading to all provinces of China and lots of countries. Unprecedented efforts and dedication have been devoted to developing effective antiviral drugs to defeat this deadly infectious disease. Creative Biolabs is also driven to provide comprehensive services and scientific support to help global customers develop a portfolio of novel and potent drugs against SARS-CoV-2.
High throughput sequencing and metagenomic analysis data (phylogenetic tree) revealed that SARS-CoV-2 belongs to the Betacoronavirus genus, Orthocoronavirinae subfamily, Coronaviridae family. After severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 is the third zoonotic human CoV. SARS-CoV-2 shares 79.5% sequence identity to SARS-CoV, 96% identity to a bat coronavirus at the whole genome level.
Patients with SARS-CoV-2 infection often exhibit symptoms of viral pneumonia, including fever, cough, runny nose, shortness of breath, bilateral lung infiltration and respiratory failure in the most severe cases. Currently, there is no specific treatment or available vaccine that protects against SARS-CoV-2. Spike (S) protein, nucleocapsid (N) protein, membrane (M) protein, and the envelope (E) protein are four major structural proteins of SARS-CoV-2. Amongst, S-protein supports strong interaction with human cell receptors, indicating the great potential as an effective target for the development of neutralizing antibodies and antiviral drugs.
Global map of confirmed 2019-nCoV cases (up to date February 4, 2020).
Creative Biolabs has rapidly integrated all-round resources and existing research results on SARS-CoV-2. Now, we can provide comprehensive antiviral drug discovery services to help our clients identify antiviral products that potently inhibit the replication of viruses in vitro, ex vivo and in vivo. Our services include but are not limited to: high-throughput screening of novel drug candidates, inhibitors discovery, neutralizing antibody development, antiviral peptide discovery and broad-spectrum antiviral drugs discovery, etc.
HTS is an effective and robust tool used for early-stage drug and therapeutic discovery. For antiviral candidates, HTS has shown great potential in broad-spectrum anti-CoV agents discovery. By screening large and entire libraries of approved drugs and pharmacologically active compounds, inhibitors, proteins and peptides, we are able to get effective antiviral agents against CoV infection. There are several types of HTS methods available, including targeted screening, diversity and high-content screening, and RNA interference (RNAi).
Playing an antiviral role through inhibiting RNA synthesis during viral replication.
Playing an antiviral role through blocking the protein synthesis and RNA replication.
Playing an antiviral role through inhibiting virus-cell membrane fusion and the subsequent virus entry.
Playing an antiviral role through preventing membrane fusion (virus-cell and cell-cell) and endosomal entry.
Playing an antiviral role through impeding the formation of double membrane vesicles (DMVs) in replication process.
Playing an antiviral role through preventing neuraminidase cleavage, thus inhibiting release of new virus particles
By suppressing the expression of the host factors essential to the infection of these viruses, the immune escape of the virus due to mutation can be avoided.
Neutralizing antibodies are useful for the prophylaxis and early treatment of emerging viral infections. S protein of CoV is the major target of neutralizing antibodies.
Fusion-inhibiting peptides binding to S proteins often act as antiviral peptides to interfere with refolding, and prevent infection.
Interferon (α and β) is the most common antiviral drug with broad-spectrum efficiency.
Anti-inflammatory drugs (such as hormones and other molecules) are a front-line treatment in the clinic.
Finding targets from the complement system is one of the important directions to the treatment of SARS-CoV-2-caused inflammatory factor storm.
SARS-CoV-2 aptamers can be used to quickly establish effective detection methods, and may also be used for the treatment of COVID-19.
Creative Biolabs offers a multi-CoV panel assay to screen drug candidates, assess the specificity of antivirals and mAbs, and to help identify and evaluate items with broad-spectrum antivirals activities. We guarantee:
If you are interested in the development of new candidate drugs for SARS-CoV-2, please feel free to contact us for more professional technical support.For Research Use Only. We do not provide services or products directly for patients.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.